Event-Driven Stocks

AVEO PHARMACEUTICALS, INC.

Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

Signs● 5 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY21FY20FY19FY18FY17FY16
Revenue$1.9M$6.0M$28.8M$5.4M$7.6M$2.5M
Operating income−$19.1M−$10.7M−$374,000−$25.4M−$28.8M−$29.4M
Net income−$22.1M−$8.4M$9.4M−$5.3M−$65.0M−$26.9M
Total assets$105.3M$66.9M$50.6M$27.9M$50.2M$27.3M
Total liabilities$59.5M$31.6M$35.8M$55.2M$91.0M$29.2M
Equity$45.9M$35.3M$14.8M−$27.2M−$40.8M−$1.9M
EPS (diluted)$-0.81$-0.52$0.61$-1.93$-6.14$-0.39
Shares out.27.1M16.1M139.0M118.9M75.9M58.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2021
Operating margin
−995.6%
Net margin
−1152.2%
Return on equity
−48.2%
Return on assets
−21.0%
Return on capital (ROCE)
−22.1%
Liabilities / assets
56.5%
Debt / equity
1.30×
Book value / share
$1.69
Revenue growth (YoY)
−68.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2021
Altman Z″ (distress)
-15.93distress
Accruals / assets
33.4%high accruals
Piotroski F-Score
1/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
22
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 5 warning● 0 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • High accruals — earnings-quality risk

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.